Clinical Trial Update: Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy trial of a gene therapy for acute myocardial infarction in Korea has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Heart Disease
• Myocardial Infarction

Snippet

Sponsor: Helixmith Co., Ltd. | Conditions: Ischemic Heart Disease, Acute Myocardial Infarction | Phase 2 | Status: WITHDRAWN